NCT02561962: A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma
Updated: Jun 13, 2022
NCT02561962: A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma
A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma
This is a first in human phase 1 multicenter open label study in subjects with relapsed or refractory multiple myeloma.
Sponsor
Amgen
Multiple Locations
International Study
ClinicalTrials.gov Identifier: NCT02561962
Official Title: A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 224 in Subjects With Relapsed or Refractory Multiple Myeloma
First Posted: September 28, 2015
Click here for details on ClinicalTrials.gov
Drug: AMG 224
Anti-BCMA Antibody-drug Conjugate AMG 224 (Code C162528)
AMG 224
AMG-224
AMG224
Anti-BCMA Antibody-drug Conjugate AMG 224
Leukemia;2021
Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma
Locations
United States, California
United States, Massachusetts
United States, New York
United States, Texas
Australia, Victoria